Zevra Therapeutics, Inc. - Common Stock (ZVRA)

Investors seeking promising opportunities in the biotech and tech sectors should keep an eye on several companies showing potential for significant market turnarounds. Recent upticks in stock prices suggest these companies could be on the cusp of substantial growth. Here's a closer look at some of these emerging players:

Zevra Therapeutics (NASDAQZVRA), a rare disease therapeutics company, uniquely combines data-driven techniques, patient needs and outside the box strategies while challenging moribund drug development protocols to bring new therapeutic relief to millions of people suffering with rare diseases. With a team of expert scientists, patient advocates, development strategists, commercialization specialists, and business development gurus – Zevra intends to become a global leader in developing and commercializing treatments for rare diseases that have limited or no therapeutic options. The company’s recent Letter to Stockholders reveals what looks like a launch code for success and suggests the company is on a fast track to drive value for all its stakeholders – patients and caregivers, stockholders, investors, and employees.

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQZVRA) on behalf of Zevra stockholders. Our investigation concerns whether Zevra has violated the federal securities laws and/or engaged in other unlawful business practices.

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQZVRA). The investigation concerns whether Zevra and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

Zevra Therapeutics (NASDAQZVRA) a rare disease therapeutics company, today announced it resubmitted its New Drug Application (“NDA”) for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pick disease type C (“NPC”) to the U.S. Food and Drug Administration (“FDA”) on Dec. 22, 2023. Based on standard NDA resubmission review timelines, the company anticipates an acknowledgment letter from the FDA that the resubmission is complete and setting the PDUFA date within 30 days. Zevra expects the NDA to be classified as Class II, which would be subject to a review period by the FDA within six months from the date of submission. “The Zevra team has worked diligently to deliver a high quality and thorough resubmission of the NDA for arimoclomol following multiple interactions with the FDA and after incorporating direction from the agency,” said Neil McFarlane, president and chief executive officer of Zevra. “We continue to accelerate our launch preparations in anticipation of FDA approval and believe we are one step closer to getting arimoclomol into the hands of patients who are seeking a treatment.”

Zevra Therapeutics (NASDAQ GS: ZVRA), a rare-disease therapeutics company, has named Neil F. McFarlane as president and CEO; McFarlane will also serve on the company’s board of directors. The new appointments are effective immediately. According to the announcement, Christal M.M. Mickle, who has been serving as interim CEO and president since June, will continue serving in her role as chief development officer. A former officer and enlisted soldier in the United States Army Reserves, McFarlane has an impressive, results-driven track record as a biopharmaceutical leader with proven ability to accelerate Zevra’s strategy of melding science, data and patient needs to create transformational therapies for patients with rare diseases. Throughout his two-decade-plus career, he has delivered sustained growth in a range of specialty and rare-disease products around the world, including the United States, Europe, Asia and Latin America. Most recently, he served as CEO and board member at Adamas Pharmaceuticals Inc. He has also worked at Retrophin Inc. (now Travere Therapeutics, Inc.), UCB Inc., Genzyme Corporation (now Sanofi) and Sangstat Medical Corporation (acquired by Genzyme). Zevra also announced the effectiveness of Joseph B. Saluri’s retirement from the board of directors.

BALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.